Analytical Data
-
Gene name
CD45
-
简介
CD45/PTPRC Protein, Mouse (HEK 293, His) expresses in HEK293 with a His tag at the N-terminus. CD45 is a transmembrane glycoprotein, expressed on almost all haematopoietic cells except for mature erythrocytes. PTPRC is an essential regulator of T and B cell antigen receptor-mediated activation[1].
- Application
-
Biological Activity
Measured by its binding ability in a functional ELISA. When Recombinant Mouse CD45 is coated at 0.5 μg/mL (100 μL/well) can bind Recombinant Mouse Galectin-1 (HY-P74131). The ED50 for this effect is 0.7718-0.7935 μg/mL. Measured by its binding ability in a functional ELISA. When Recombinant Mouse CD45 is coated at 0.5 μg/mL (100 μL/well) can bind Recombinant Mouse Galectin-1 (HY-P74131). The ED50 for this effect is 0.7718 μg/mL.
-
Alternative Names
rMuReceptor-type tyrosine-protein phosphatase C/CD45, His; B220; CD45 antigen; CD45; CD45R; LCA; L-CA; LY5; protein tyrosine phosphatase, receptor type, C; PTPRC; receptor-type tyrosine-protein phosphatase C
-
Species
Mouse
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P06800
-
Expression Region
Q26-K566
-
AA Sequence
QTPTPSDELSTTENALLLPQSDPLPARTTESTPPSISERGNGSSETTYHPGVLSTLLPHLSPQPDSQTPSAGGADTQTFSSQADNPTLTPAPGGGTDPPGVPGERTVPGTIPADTAFPVDTPSLARNSSAASPTHTSNVSTTDISSGASLTTLTPSTLGLASTDPPSTTIATTTKQTCAAMFGNITVNYTYESSNQTFKADLKDVQNAKCGNEDCENVLNNLEECSQIKNISVSNDSCAPATTIDLYVPPGTDKFSLHDCTPKEKANTSICLEWKTKNLDFRKCNSDNISYVLHCEPENNTKCIRRNTFIPERCQLDNLRAQTNYTCVAEILYRGVKLVKNVINVQTDLGIPETPKPSCGDPAARKTLVSWPEPVSKPESASKPHGYVLCYKNNSEKCKSLPNNVTSFEVESLKPYKYYEVSLLAYVNGKIQRNGTAEKCNFHTKADRPDKVNGMKTSRPTDNSINVTCGPPYETNGPKTFYILVVRSGGSFVTKYNKTNCQFYVDNLYYSTDYEFLVSFHNGVYEGDSVIRNESTNFNAK
-
Protein Length
Extracellular Domain
-
Molecular Weight
120-160 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD45, also known as leukocyte common antigen, is a crucial glycoprotein expressed on the surface of all nucleated hematopoietic cells, playing a significant role in immune response regulation. It acts as a receptor-type protein tyrosine phosphatase, modulating signaling pathways involved in cell activation, differentiation, and proliferation. The research surrounding CD45 has gained prominence due to its implications in various immunological diseases and conditions, including autoimmune disorders, lymphoproliferative diseases, and cancer. Given its essential role in T and B cell signaling, understanding CD45's structure and function is vital for developing therapeutic approaches. Recombinant CD45 proteins, produced via genetic engineering methods, allow for a deeper investigation into the protein's functional domains and interaction mechanisms. These recombinant forms can also serve as valuable tools for creating specific antibodies or as potential targets for immunotherapy. The ability to manipulate and study CD45 in vitro opens pathways for elucidating the complexities of immune cell signaling and offers prospects for innovative treatments in diseases characterized by immune dysregulation.
